LUM-201
Sponsors
Lumos Pharma Inc., Lumos Pharma, Massachusetts General Hospital
Conditions
Growth Hormone DeficiencyGrowth Hormone Deficiency (GHD)Idiopathic Growth Hormone DeficiencyNAFLDNASH - Nonalcoholic SteatohepatitisNonalcoholic Fatty LiverObesity & Overweight
Phase 2
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
CompletedNCT04614337
Start: 2020-12-31End: 2024-09-04Updated: 2026-06-17
PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)
Active, not recruitingNCT04806854
Start: 2021-07-14End: 2030-07-31Target: 24Updated: 2023-10-04
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
CompletedNCT05250063
Start: 2022-02-18End: 2025-01-22Updated: 2026-05-15
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
CompletedNCT05364684
Start: 2022-08-10End: 2024-12-23Updated: 2026-01-06
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
Enrolling by invitationNCT05796440
Start: 2023-08-01End: 2028-04-30Target: 60Updated: 2024-02-15
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency
RecruitingCTIS2023-504020-25-00
Start: 2023-12-28Target: 21Updated: 2025-08-20
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
Not yet recruitingNCT07754045
Start: 2027-02-15End: 2028-02-15Target: 202Updated: 2026-08-10
Phase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
RecruitingNCT06948214
Start: 2026-05-20End: 2028-01-01Target: 150Updated: 2026-09-04
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
Not yet recruitingNCT07129759
Start: 2027-02-01End: 2030-02-01Target: 150Updated: 2026-07-08